Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Gyre Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 69 | 2 | 66 | −1 |
| Shares | 20.2M | 152.2K | 18.4M | −1.70M (−8.5%) |
| Value | $87.7M | $659.0K | $75.7M | −$11.3M (−13.0%) |
2 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Gyre Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pura Vida Investments, LLC | 372,582 | $1.53M | 0.12% |
| Sabby Management, LLC | 105,742 | $435.0K | 0.10% |
| Johnson & Johnson | 66,951 | $275.0K | 0.02% |
| Citadel Advisors LLC | 65,409 | $268.0K | 0.00% |
| J. Goldman & Co LP | 60,755 | $250.0K | 0.02% |
| Walleye Capital LLC | 40,520 | $167.0K | 0.01% |
| CSS LLC | 33,549 | $138.0K | 0.01% |
| Virtu Financial LLC | 29,103 | $120.0K | 0.01% |
| Cherry Creek Investment Advisors, Inc. | 20,000 | $82.0K | 0.05% |
| Walleye Trading LLC | 13,507 | $56.0K | 0.00% |
| Commonwealth Equity Services, LLC | 10,000 | $41.0K | 0.00% |
| Silverarc Capital Management, LLC | 10,000 | $41.0K | 0.02% |
| Total Clarity Wealth Management, Inc. | 2,000 | $8.00K | 0.00% |
| American Portfolios Advisors | 215 | $884 | 0.00% |
| FMR LLC | 1 | $0 | 0.00% |
Sold out (16)
Institutions that held Gyre Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Verition Fund Management LLC | 387,101 | $1.68M |
| Deutsche Bank AG | 194,933 | $844.0K |
| Tibra Equities Europe Ltd | 79,200 | $343.0K |
| Susquehanna International Group, LLP | 55,219 | $239.0K |
| Trexquant Investment LP | 32,220 | $140.0K |
| Parametric Portfolio Associates LLC | 21,019 | $91.0K |
| Advisory Services Network, LLC | 19,700 | $85.0K |
| Quantitative Systematic Strategies LLC | 16,277 | $70.0K |
| XTX Topco Ltd | 15,265 | $66.0K |
| Charles Schwab Investment Management Inc | 13,113 | $57.0K |
| Group One Trading, L.P. | 6,508 | $28.0K |
| UBS Group AG | 2,609 | $11.0K |
| Royal Bank of Canada | 2,174 | $9.00K |
| Federation des caisses Desjardins du Quebec | 1,125 | $4.87K |
| New York State Common Retirement Fund | 257 | $1.00K |
| Quadrant Capital Group LLC | 336 | $1.00K |
Not filed for Q3 2021 yet (2)
Institutions that held Gyre Therapeutics, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| M Holdings Securities, Inc. | 85,202 | $369.0K |
| Johnson & Johnson Innovation - JJDC, Inc. | 66,951 | $290.0K |